image
Healthcare - Biotechnology - NASDAQ - US
$ 0.2701
-17.9 %
$ 4.33 M
Market Cap
-0.18
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one INDP stock under the worst case scenario is HIDDEN Compared to the current market price of 0.27 USD, Indaptus Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one INDP stock under the base case scenario is HIDDEN Compared to the current market price of 0.27 USD, Indaptus Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one INDP stock under the best case scenario is HIDDEN Compared to the current market price of 0.27 USD, Indaptus Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart INDP

image
$1.1$1.1$1.0$1.0$0.9$0.9$0.8$0.8$0.7$0.7$0.6$0.6$0.5$0.5$0.4$0.4$0.3$0.3$0.2$0.2Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
0 REVENUE
0.00%
-15.4 M OPERATING INCOME
6.18%
-15 M NET INCOME
2.60%
-12.3 M OPERATING CASH FLOW
8.07%
0 INVESTING CASH FLOW
0.00%
4.75 M FINANCING CASH FLOW
0.00%
0 REVENUE
0.00%
-4.57 M OPERATING INCOME
-9.61%
-4.53 M NET INCOME
-9.72%
-5.05 M OPERATING CASH FLOW
-48.63%
0 INVESTING CASH FLOW
0.00%
3.15 M FINANCING CASH FLOW
74.90%
Balance Sheet Indaptus Therapeutics, Inc.
image
Current Assets 6.62 M
Cash & Short-Term Investments 5.79 M
Receivables 0
Other Current Assets 832 K
Non-Current Assets 720 K
Long-Term Investments 0
PP&E 82.2 K
Other Non-Current Assets 638 K
78.85 %11.33 %8.70 %Total Assets$7.3m
Current Liabilities 3.39 M
Accounts Payable 870 K
Short-Term Debt 168 K
Other Current Liabilities 2.36 M
Non-Current Liabilities 0
Long-Term Debt 0
Other Non-Current Liabilities 0
25.64 %4.96 %69.40 %Total Liabilities$3.4m
EFFICIENCY
Earnings Waterfall Indaptus Therapeutics, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 15.4 M
Operating Income -15.4 M
Other Expenses -344 K
Net Income -15 M
00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)(16m)(16m)000(15m)(15m)344k(15m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-380.80% ROE
-380.80%
-204.69% ROA
-204.69%
-373.57% ROIC
-373.57%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Indaptus Therapeutics, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)(45m)(45m)(50m)(50m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -15 M
Depreciation & Amortization 735
Capital Expenditures 0
Stock-Based Compensation 2.31 M
Change in Working Capital 392 K
Others -81.8 K
Free Cash Flow -12.3 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Indaptus Therapeutics, Inc.
image
INDP has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 17
6. Ownership
Insider Ownership Indaptus Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced the sale of approximately $2.3 million in aggregate principal amount of convertible promissory notes and accompanying warrants. This transaction is being led by a healthcare-focused institutional investor in an ongoing offering in which the Company is seeking to raise up to $5 million in gross proceeds. globenewswire.com - 1 week ago
Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, announces that the first patient has been dosed in the expansion arm of its Phase 1b/2 clinical trial evaluating Decoy20 in combination with BeOne's (formerly known as Beigene) PD-1 checkpoint inhibitor, tislelizumab. This newly activated arm of the trial will assess safety, dose optimization, and early signs of anti-tumor activity in patients with advanced solid tumors, previously treated with a checkpoint inhibitor or with tumors typically unresponsive to a checkpoint inhibitor. globenewswire.com - 2 weeks ago
Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update. globenewswire.com - 1 month ago
Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, announces that its Founder and Chief Scientific Officer, Michael Newman, Ph.D., will serve as an Expert Speaker and Chair of Day 2 at the 6th Annual Cytokine-Based Drug Development Summit taking place May 15-16, 2025 in Boston. globenewswire.com - 1 month ago
Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company pioneering innovative therapies for cancer and viral infections, announces that its chief medical officer, Roger Waltzman, M.D., M.B.A. will be moderating a panel at the annual CMO360 Summit, being held April 7-8 in Boston. globenewswire.com - 2 months ago
Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20 NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today provided an update on key pharmacodynamic findings from the weekly dosing cohort of its ongoing Phase 1 trial of Decoy20. As announced in last week's earnings release, the Company has now enrolled more than 20 patients in the weekly dosing cohort, marking a key milestone in the trial. globenewswire.com - 3 months ago
Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today announced that it has advanced to a new expansion arm of its Phase 1b/2 clinical trial of Decoy20. This expansion will evaluate the combination of Decoy20 with BeiGene's PD-1 checkpoint inhibitor, tislelizumab, with a focus on safety, dose optimization, and early signs of anti-tumor activity. globenewswire.com - 3 months ago
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announces financial results for the fourth quarter and fiscal year ended December 31, 2024 and provides a corporate update. globenewswire.com - 3 months ago
Registration Is Now Open For Tribe Public's Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025 NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ: INDP) announces that Indaptus' CEO, Jeffrey Meckler, will present at Tribe Public's Webinar Presentation and Q&A Event titled “Keys To The Kingdom: Unlocking The Power Of Your Immune System.” The Event is scheduled to begin at 9:00am pacific/12:00pm eastern on Monday, March 17, 2025. To register to join the complimentary event, please visit the Tribe Public LLC at INDP-KEYS.TribePublic.com . globenewswire.com - 3 months ago
Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, announced today that it has secured new patent approvals in China, Japan and Israel for its Decoy platform. These patents cover the use of Decoy bacteria compositions for preventing or treating Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) – two diseases that continue to pose major global health challenges. The patents also extend to combination therapies with a variety of both approved and investigational treatments. globenewswire.com - 3 months ago
Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today announced that Michael Newman, Founder and Chief Scientific Officer, will present at the 10th Annual Innate Killer Summit, taking place from March 3-5, 2025, in San Diego, California. Dr. Newman will deliver a scientific presentation on Tuesday, March 4, 2025, titled, “Employing Attenuated & Killed Gram-Negative Bacteria to Induce NK-Mediated Anti-Tumor Immunity. globenewswire.com - 3 months ago
Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20 NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today announced the Company has received Clinical Trial Authorization from Health Canada to initiate its clinical trial for its lead asset, Decoy20. This approval will allow the Company to expand its ongoing U.S. clinical trial, INDP-D101, to Canadian sites, broadening patient recruitment and enhancing its clinical research program. The trial will enroll patients in Canada under the current protocol, which involves weekly dosing of Decoy20. Indaptus also plans to submit an amendment to Health Canada to incorporate its upcoming combination trial, which pairs Decoy20 with Beigene's PD-1 checkpoint inhibitor, tislelizumab. globenewswire.com - 4 months ago
8. Profile Summary

Indaptus Therapeutics, Inc. INDP

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 4.33 M
Dividend Yield 0.00%
Description Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
Contact 3 Columbus Circle, New York City, NY, 10019 https://indaptusrx.com
IPO Date Aug. 4, 2015
Employees 7
Officers Mr. Walt Addison Linscott Esq. Chief Operating Officer Dr. Michael J. Newman Ph.D. Founder, Chief Scientific Officer & Director Dr. Roger J. Waltzman M.B.A., M.D. Chief Medical Officer Mr. Jeffrey A. Meckler J.D. Chief Executive Officer & Director Mr. Nir Sassi Chief Financial Officer, Secretary & Treasurer